EUVIMEDEUVIMED entdecken
Crossref

The significance of Syndecan 1, a new marker for endothelial dysfunction, in cases of fetal growth retardation

Yüksel Oğuz iD, Recep Taha Ağaoğlu, Can Ozan Ulusoy, Dilara Kurt, İzzet Özgürlük, Çağanay Soysal, Zehra Yılmaz Vural iD, Kadriye Yakut Yücel

American Journal of Reproductive Immunology · 2024

DOI: 10.1111/aji.13858 ↗

Kurz gefasst

Fachartikel in der Zeitschrift American Journal of Reproductive Immunology, 2024. Verfasst von Yüksel Oğuz und 7 weiteren Autor:innen. Beteiligte Einrichtung: Ministry of Health, Etlik City Hospital, Perinatology Department, Ankara, Turkey. Hauptthemen laut MEDLINE: Syndecan-1, Fetal Growth Retardation, Biomarkers. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 23 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Problem In the current study we aimed to investigate Syndecan 1 (SDC1) levels in pregnant women diagnosed with fetal growth restriction (FGR) and the relationship between SDC1 levels and clinical and doppler parameters in FGR cases associated with endothelial dysfunction, angiogenesis and uteroplacental insufficiency Method of Study A total of 90 pregnant women included in the study, (45 with FGR, 45 healthy control) matched by week of gestation and maternal age. Venous blood samples were collected and plasma concentrations of SDC1 were determined by a specific immunoassay. Doppler examination was performed to evaluate the relationship between the SDC1 levels and placental blood supply.

Results

Doppler parameters; mean UtA‐PI ( p < .001), CPR ( p = .002) and CPUR ( p < .001) were different between the groups, however MCA PI, umbilical artery PI and umbilical artery S/D were not ( p > .05). While gestational age at delivery, birth weight, APGAR score at 1 and 5 min were significantly lower (all, p < .001) in the study group, non‐reassure fetal heart rate tracing ( p = .09) and NICU admission ( p = .02) were significantly higher. SDC 1 level was 2,00 ± 1,47 ng/mL and 2,34 ± 1,12 ng/mL in the FGR and control groups, respectively ( p = .008). In the study group SDC 1 level was 1,69 ± 2,00 in those with gestational age below 32 weeks and 2,13 ± 1,18 in those with gestational age above 32 weeks and there was a statistically significant difference between the groups ( p = .015). Plasma SDC 1 concentration of 2,1850 ng/mL or less had a sensitivity of 70%, a specificity of 72%, area under the ROC curve .65 (p < .005).

Conclusions

Low maternal plasma SDC1 level may be associated with placental insufficiency and FGR. Low levels of SDC1 may be helpful as a predictor for the development of FGR during gestation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Syndecan-1Fetal Growth RetardationBiomarkersHumansFemalePregnancyAdultGestational AgeInfant, NewbornUmbilical ArteriesPlacentaEndothelium, Vascular

Stichwörter der Autor:innen

Syndecan 1dopplerendothelial disfunctionfetal growth restrictionumbilical arteryuterine artery

Substanzen

Syndecan-1BiomarkersSDC1 protein, human

Autor:innen und Institutionen

  • Ministry of Health, Etlik City Hospital, Perinatology Department, Ankara, Turkey.

ORCID-Profile: Yüksel Oğuz, Zehra Yılmaz Vural

Zitieren

APA

Oğuz, Y., Ağaoğlu, R. T., Ulusoy, C. O., Kurt, D., Özgürlük, İ., Soysal, Ç., Yılmaz Vural, Z., & Yakut Yücel, K. (2024). The significance of Syndecan 1, a new marker for endothelial dysfunction, in cases of fetal growth retardation. American Journal of Reproductive Immunology. https://doi.org/10.1111/aji.13858

Vancouver

Oğuz Y, Ağaoğlu RT, Ulusoy CO, Kurt D, Özgürlük İ, Soysal Ç, et al. The significance of Syndecan 1, a new marker for endothelial dysfunction, in cases of fetal growth retardation. American Journal of Reproductive Immunology. 2024. doi:10.1111/aji.13858

BibTeX
@article{Ouz2024,
  author = {Oğuz, Yüksel and Ağaoğlu, Recep Taha and Ulusoy, Can Ozan and Kurt, Dilara and Özgürlük, İzzet and Soysal, Çağanay and Yılmaz Vural, Zehra and Yakut Yücel, Kadriye},
  title = {The significance of Syndecan 1, a new marker for endothelial dysfunction, in cases of fetal growth retardation},
  journal = {American Journal of Reproductive Immunology},
  year = {2024},
  doi = {10.1111/aji.13858}
}
Kostenlos starten →